Tasly announced that due to work adjustments, Zhou Hui will step down as chairman but remain a director, a member of the board's strategy and ESG committee, and a member of the compensation and assessment committee. The company's ninth board of directors approved at its 23rd meeting the election of non-independent director Cai Jinyong as chairman of the ninth board, and Cai Jinyong will no longer serve as general manager. Due to work adjustments, Zhong Jiang will step down as a non-independent director, Xi Kai will step down as an employee representative director, and the company plans to appoint Xi Kai as a non-independent director. At the same time, the board has appointed Xi Kai as general manager. In the first quarter of 2026, Tasly achieved revenue of 2.165 billion yuan and net profit attributable to the parent company of 370 million yuan.
Tasly Pharmaceutical Group Co LtdManagement changes and Q1 results reported, but impact on company unclear.
